Search alternatives:
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
13861
-
13862
-
13863
-
13864
-
13865
-
13866
-
13867
-
13868
-
13869
-
13870
-
13871
HDAC and proteasome inhibition leads to apoptosis via pro-apoptosis protein activation, ROS production and caspase activation.
Published 2017“…(D) The low-dose quisinostat/bortezomib drug combination brings about a significant decrease in the viability of primary synovial sarcoma cells (83-SS) as compared to matched normal muscle cells derived from the same patient (83-muscle). …”
-
13872
hMSC adjunctive therapy failed to decrease pulmonary inflammation or prevent ALI compared to antiviral therapy alone in experimental severe influenza.
Published 2013“…<p>Eight-week old male C57Bl/6 mice infected with 425 EID<sub>50</sub> influenza A/PR/8 virus were administered 2.5 mg/kg oseltamivir in 100 ul ddH2O via gavage, 1×daily for 5 days, beginning day 2 P.I., with or without hMSC administration (5×10<sup>5</sup> cells) on day 2 P.I. and sacrificed on day 7 P.I. …”
-
13873
A Hierarchical Contact–Electrification Interface Based on Gradient Micro-/Nanostructured Hydrogel for Cardiovascular Disease Monitoring
Published 2025“…Importantly, a preliminary 10 day blood pressure test on 22 volunteers showed an error margin of less than ±5 mm Hg, demonstrating its potential as a cardiovascular health product.…”
-
13874
A Hierarchical Contact–Electrification Interface Based on Gradient Micro-/Nanostructured Hydrogel for Cardiovascular Disease Monitoring
Published 2025“…Importantly, a preliminary 10 day blood pressure test on 22 volunteers showed an error margin of less than ±5 mm Hg, demonstrating its potential as a cardiovascular health product.…”
-
13875
-
13876
AUC of various models to predict imeglimin efficacy for liver function evaluated by ROC curves.
Published 2025Subjects: -
13877
The details of terminal deoxynulceotidyl transferase nick-end-labeling (TUNEL) staining.
Published 2023Subjects: -
13878
Result of terminal deoxynulceotidyl transferase nick-end-labeling (TUNEL) staining.
Published 2023Subjects: -
13879
-
13880